The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.
Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:
Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.
We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.
More top news
MI5 face mounting pressure over claims the IS executioner 'Jihadi John', named yesterday as a London graduate, was known to them
Labour leader Ed Miliband is due to set out his party's plans on how it would cut tuition fees.
New drug driving laws are to come into effect next week, including laws on some prescribed medications.